Crinetics Pharmaceuticals (CRNX) Change in Accured Expenses (2017 - 2026)

Crinetics Pharmaceuticals has reported Change in Accured Expenses for 10 years, with the latest figure at -$12.1 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 789.68% year-over-year to -$12.1 million; the trailing twelve-month figure through Mar 2026 stood at $18.3 million (up 71.52% YoY), and the FY2025 full-year result was $29.0 million, up 117.64% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$12.1 million, down from $11.2 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $12.5 million in Q2 2025, with the low at -$12.1 million in Q1 2026.
• Average Change in Accured Expenses over 5 years is $3.2 million, with a median of $4.1 million recorded in 2022.
• Year-over-year, Change in Accured Expenses jumped 866.13% in 2025 and slumped 789.68% in 2026.
• Tracing CRNX's Change in Accured Expenses over 5 years: stood at $4.1 million in 2022, then plunged by 53.47% to $1.9 million in 2023, then surged by 221.89% to $6.1 million in 2024, then jumped by 82.73% to $11.2 million in 2025, then plunged by 207.95% to -$12.1 million in 2026.
• The last three Change in Accured Expenses figures came in at -$12.1 million (Q1 2026), $11.2 million (Q4 2025), and $6.6 million (Q3 2025), per Business Quant data.

Peer Comparison